Signalling and Acquired Resistance to Targeted Cancer Therapeutics
Conference - Cambridge, United Kingdom
Tumour cells rapidly evolve to acquire resistance to new, targeted therapeutics such as protein kinase inhibitors. Understanding such ‘acquired resistance’ has obvious clinical relevance but also reveals the plasticity of signalling pathways and their ability to remodel through feedback and cross-talk. This meeting will highlight advances in understanding how tumour cells adapt to inhibition of specific signalling pathways and the role this plays in acquired resistance. Topics: RAF-MEK-ERK signalling Tyrosine kinases and their inhibitors TOR/PI3K inhibitors Kinome reprogramming Cell survival/cell death signalling Systems and computational biology approaches
Sponsoring Institution: Biochemical Society
(Courtesy of Biochemical Society's logo, via cvent.com)
For more information, please visit: http://www.biochemistry.org/Conferences/AllConferences/tabid/379/View/Programme/Filter/0%2040FC/MeetingNo/SA154/Default.aspx
Sunday, January 5, 2014 - Tuesday, January 7, 2014 (13:00 - 13:30)
Robinson College, Cambridge WC1N 2JU, United Kingdom
Contact: Sarah Umar (conferences@biochemistry.org)
Phone: 2076852450
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.